Abstract
Twenty-six patients with poor-risk Kaposi's sarcoma and AIDS were treated with epirubicin 90 mg/m2 intravenously every 3 weeks. One patient achieved complete response and 10 achieved partial response (overall response rate 42.3%). The median time to treatment failure was 22 weeks. The dose-limiting toxicity was neutropenia.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications*
-
Adult
-
Aged
-
Drug Evaluation
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Epirubicin / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Ontario
-
Prospective Studies
-
Remission Induction
-
Sarcoma, Kaposi / drug therapy*
-
Sarcoma, Kaposi / etiology
-
Sarcoma, Kaposi / mortality
-
Survival Rate